Rxbio, Inc.

UEI: DB9LSMAHKNJ8
CAGE: 4CJP9
Primary NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration: Expired Apr 3, 2024

Company facts

Self-certified in SAM.gov: For Profit Organization
Entity structure: Corporate Entity (Not Tax Exempt)
SAM.gov registration date: Mar 26, 2006

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated Sep 1, 2024.

Contract awards

Award	Agency	Obligated	Awarded
IND-enabling development of RX100 as a medical countermeasure for gastrointestinal acute radiation syndrome. 75N93018C00052	National Institute of Allergy and Infectious Diseases (NIH)	$4,591,512	Sep 1, 2018
Definitive Contract HHSN261201100036C	National Cancer Institute (NIH)	$194,797	Sep 23, 2011
Rxbio RX100 HHSO100201100036C	Office of the Assistant Secretary for Preparedness and Response	$14,057,437	Aug 27, 2011
Selling agreement - lab space V614S0015	Veterans Integrated Service Network 9 (VHA)	$0	Jun 7, 2005

Grant awards

Award	Agency	Obligated	Awarded
Targeted therapies for the treatment of GI-ARS diarrhea R41DK125208	National Institute of Diabetes and Digestive and Kidney Diseases (NIH)	$252,128	Sep 18, 2020
The anti-diarrheal potential of a LPA analog RX100 R43DK105719	National Institutes of Health	$222,829	Sep 17, 2015
Development of RX100 as novel medical countermeasure for acute radiation syndrome R43AI118004	National Institutes of Health	$297,087	Mar 1, 2015
Non toxic insect resistant textiles for military clothing W911QY1210008	Department of Defense	$734,075	Apr 16, 2012
RX 100: in vitro mechanism of action and preclinical pharmocokinetic W911QY1210006	Department of the Army	$1,049,055	Apr 11, 2012

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Rxbio, Inc. registered in SAM.gov?

Rxbio, Inc.'s SAM.gov registration expired on April 3, 2024.

What is Rxbio, Inc.'s CAGE code?

Rxbio, Inc.'s CAGE code is 4CJP9, and its Unique Entity ID (UEI) is DB9LSMAHKNJ8.

What is Rxbio, Inc.'s most recent federal award?

Rxbio, Inc.'s most recent federal grant award is Targeted therapies for the treatment of GI-ARS diarrhea (R41DK125208), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 18, 2020.

On GovTribe

See Rxbio, Inc.'s full federal record

Federal contract awards
IDV awards
Federal grant awards
Funding analysis by agency, NAICS and set-aside
Similar vendors

Try for free Login

Find teaming partners on GovTribe